European advisory group backs Sanofi's Zynquista in T1D

|About: Lexicon Pharmaceutical... (LXRX)|By:, SA News Editor

The European Medicines Agency's advisory group CHMP has adopted a positive opinion recommending Sanofi's (NASDAQ:SNY) Zynquista (sotagliflozin) as an adjunct to insulin to improve glycemic control in overweight type 1 diabetics (Body Mass Index ≥ 27 kg/m2) who have failed to achieve adequate glycemic control despite optimal insulin therapy.

A final decision from the European Commission usually takes ~60 days.

Related ticker: Lexicon Pharmaceuticals (NASDAQ:LXRX) (+9% premarket).

Subscribe for full text news in your inbox